Juno Therapeutics Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Juno Therapeutics (JUNO) Misses Q1 EPS by 26c
May 9, 2016 4:11 PM EDTJuno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.78), $0.26 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $4.65 million.
Juno expects 2016 cash burn, excluding cash inflows or outflows from business development activities, to be between $220... More
